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Introduction
Search for and development of highly efficient and safe 
medicines for management of pain of various natures is still 
one of the priorities of modern pharmacology [1, 2]. 4-oxo 
(amino-) quinazoline derivatives have proved to be quite 
promising among the classes of chemicals. According to the 
research literature [3, 4], this class of compounds have shown 
cerebro- and actoprotective and antinociceptive properties, 
and appeared to be low-toxic substances [5]. In previous 
screening studies of pain models caused by electrical (pulse) 
stimulation of rectal mucosa and thermal stimulation of 
rat tail, we found two leading compounds (PC-66 and PC-
199) with pronounced analgesic effect within a range of new 
4-oxo (amino-) quinazolin derivatives, which appeared to be 
equivalent to diclofenac sodium and ketorolac both in the 
efficacy and effect duration [6]. However, the PC-66 com-
pound revealed to be much safer for the gastric mucosa than 
PC-199 [7]. This became the basis for further in-depth study 
of the pharmacological properties of PC-66 compound as an 
anesthetic medicine.
Study objective – to evaluate the analgesic effect of the 
above substance compared with ketorolac and diclofenac so-
dium in various rat pain models.
Material and methods
 Experiments were conducted on 101 male 180-210-gram 
Wistar rats bred at vivarium of DU ‘Instytut farmakolohii ta 
toksykolohii NAMN Ukrainy’ (State institution “Institute of 
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Abstract
Background: Screening studies have revealed in new 3-(2-R1-6-R2-4-oxyquinoline-3(4H)-yl)alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 
compound) expressive analgesic properties without any damaging effects on the stomach. Therefore, in-depth study of the pharmacological properties 
of PC-66 compound as a pain management agent is considered topical.  Objective of the study – to evaluate a pain-killing effect of PC-66 compound 
compared to ketorolac and diclofenac sodium on various rat pain models.
Material and methods: In experiments on 101 Wistar male rats (180-210 g) of somatic model (tail-flick) and neuropathic pain model (ligation of the 
sciatic nerve), and formalin test (5% formalin solution, 0.1 ml subplantarly) we investigated the antinociceptive activity of the PC-66 compound (1.0 mg/
kg) versus ketorolac (2.4 mg/kg) and diclofenac (4.0 mg/kg) administered intraperitoneally.
Results: In the tail-flick model, PC-66 compound presented significant growth of PT at Hour 1 and Hour 2 by 40.6% and 50.6%, respectively. The analgesia 
effect of the test compound was superior to the one of diclofenac sodium, but inferior to ketorolac at Hour 1 and Hour 2, yet surpassed it by duration 
of action. In the formalin test model, analgesic effect of compound PC-66 was the most evident in the first (central) phase, and slightly changed the 
latent period and duration of the second phase of the test, while diclofenac mostly influenced Phase II (inflammatory) of the formalin test. In the model 
of neuropathic pain, compound PC-66 also demonstrated pronounced pain-killing effect: PT of subject rat limb grew on average by 46.7% in 2 hours 
following intraperitoneal administration. For this activity, PC-66 was slightly inferior to ketorolac, which caused PT growth by 51.9%.
Conclusions: new 3-(2-R1-6-R2-4-oxyquinoline-3(4H)-yl) alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 compound) presented distinct analgesic 
effect both in somatic and neuropathic pain models. 
Key words: carboxylic acid derivative (PC-66 compound), analgesic effect, rat pain models.
Pharmacology and Toxicology of AMS of Ukraine”), kept in 
standard conditions of vivarium on traditional diet with 12 
–hour light-and-dark regime and access to water ad libitum. 
All experiments were carried out in compliance with the 
required bioethical standards. The following nociception 
models were used in the study: thermal stimulation model 
(tail-flick) for registration of changes in the latent period of 
tail flicks against the focused beam of light (pain threshold, 
PT) measured in seconds [9]; comparative benchmarks for 
duration of latent period and its changes in 1, 2, 4 and 6 
hours after administration of test compound and reference 
medicine; and the model of neuropathic pain after ligation 
of the sciatic nerve [9]. The intensity of mechanical hyperal-
gesia was evaluated on Day 14 after surgery using Dolorim-
eter Baseline, USA. The pain threshold (PT) in subject and 
intact limbs was taken as minimal pressure on rat foot (g/
mm2), which caused painful reaction in animals (vocaliza-
tion and/or foot flick). More information about central and 
peripheral components of analgesic response was obtained 
after the formalin test (5% formalin solution, 0.1 ml sub-
plantarly). The monitoring lasted 60 minutes after algogenic 
substance administration. We registered I and II phase la-
tent period duration, and the total duration of pain in each 
phase of the test. Single dose of PC-66 compound, ketorolac 
and diclofenac were administered intraperitoneally. Ani-
mals in the control group received equivolumic quantities 
of solvents. The results were processed by methods of varia-
tion statistics using STATISTICA 8.0 software and nonpara-
metric methods of analysis [10].
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Results and discussion
The results of screening studies of PC-66 compound and 
reference medicines allowed us to define conditionally-effec-
tive antinociceptive doses of these substances administered 
intraperitoneally, which were 1.0, 2.4, and 4.0 mg/kg for PC-
66, ketorolac and diclofenac sodium, respectively. Therefore, 
these same doses of studied substances were used for further 
study of analgesic effect.
The first phase of thermal stimulation test (tail-flick) in-
vestigated the extent and duration of PC-66 effect compared 
to ketorolac and diclofenac sodium. The results presented 
presumable overrun of rat PT with quinazoline derivative 
well in an hour after administration (40.6%). Maximum 
growth of antinociceptive effect was registered at Hour 2 (+ 
50.6%), which decreased gradually and at Hour 6 was 20.4% 
compared to the baseline (fig. 1). The analgesia effect of the 
test compound was found superior to diclofenac at all times 
of the study, but inferior to ketorolac at Hour 1 and 2 af-
ter administration, yet exceeding the duration of the above 
effect (at Hour 6, the PT growth influenced by PC-66 was 
20.4%, versus 8.93% influenced by ketorolac).
Fig. 1.  Behaviour of analgesic effect of PC-66, ketorolac and 
diclofenac sodium administered intraperitoneally at suppositive 
– effective doses.
The obtained data led to further in-depth studies of an-
algesic effect in formalin test оn rats, which allowed distin-
guishing central and peripheral components of antinocicep-
tive effect in more details. The results showed that subplantar 
administration of formalin caused pain reaction in intact 
animals that started in average 0.69 ± 0.36 minutes follow-
ing the procedure. Pain reaction manifested in raising and 
swinging the subject leg (Phase 1), as well as in biting and 
licking (Phase 2). Total duration of pain was 5.02 ± 0.42 
minutes. After that, the animals calmed down, and about 20 
minutes did not present any change in behavior. Then again 
the signs of pain reaction returned, clinically manifested in 
two phases with total duration of 31.9 ± 2.36 minutes. At 
the end of the monitoring period (60 minutes), signs of pain 
in considerable number of rats did not abate. The animals, 
intraperitoneally administered solvents (control group) in-
stead of study medicines, presented all above-mentioned 
clinical signs of pain reaction, not different in severity and 
duration of Phase I and II latent periods from intact animals 
(tab. 1).
Table 1
Analgesic activity of PC-66 (1 mg/kg IP) and diclofenac 
(4 mg/kg IP) in rat model formalin test (M ± m, n = 10)
Group of 
animals










Intact animals 1.69±0.36 5.02±0.45 21.3±2.45 31.9±2.36
Control  
(solvent)
1,67±0.29 5.14±0.61 21.2±1.21 32.0±1.09
Diclofenac
1.79±0.16 5.64±0.28 27.3±2.19* 18.7±2.58*
PC-66
2,41±0,28# 4,48±0,29# 22,2±1,04# 29,4±1,15#
Notes: * – statistically significant differences against the control 
(p<0.05), # – statistically significant differences against diclofenac 
(p<0.05).
Instead, administration of PC-66 and diclofenac sodium, 
significantly changed pain behavior of animals. PC-66 sig-
nificantly (44.3%) extended the duration of latent period of 
phase I in formalin test and statistically significantly (12.8%) 
reduced the duration of this phase, which substantionally 
characterized central mechanisms of antinociceptive action. 
Unlike PC-66, diclofenac sodium practically did not influ-
ence the duration of this phase. Having analyzed the influ-
ence of PC-66 and diclofenac on phase II of the formalin 
test, you can see that the tested compound influenced the 
duration of the inflammatory phase much weaker than di-
clofenac. Thus, the increase in average latency period and 
reduction of the total duration of pain reaction changed in-
significantly (4.7 and 8.1%, respectively), while the latent pe-
riod influenced by diclofenac demonstrated statistically sig-
nificant growth by 28.8%, while duration of pain decreased 
by 41.5% compared to control (p<0.05).
The received data showed that PC-66 demonstrated an-
algesic properties in the rat model formalin test, manifested 
mostly in the Phase I of the model pathology, which involved 
mainly central antinociceptive mechanisms and slightly 
reduced latent period and duration of phase II of the test. 
These properties were different from non-steroid anti-in-
flammatory effect of diclofenac sodium, which altered Phase 
II (inflammatory), which mechanisms were influenced by 
mediators of inflammatory response, mainly prostaglandins, 
leukotrienes, etc.
Another important aspect of analgesic action of biologi-
cally active compounds is their effect on the neuropathic 
pain model. According to the results of the study, on Day 
14 after nerve ligation, animals developed a chronic pain 
syndrome manifested in behavioral reactions of rats and 
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decrease of pain threshold in subject limbs by 21-24%, in 
average, compared to intact limbs (tab. 2). Under these con-
ditions, PC-66 demonstrated expressed analgesic effect, as 
evidenced by increase of PT in subject limbs 2 hours after 
intraperitoneal administration by average 46.7%, compared 
with the index before administration of the substance. For 
this activity, PC-66 was slightly inferior to ketorolac, which 
presented PT growth by 51.9% (p <0.05).
Conclusions
Thus, we have received information that confirmed pret-
ty high analgesic effect of new 3-(2-R1-6-R2-4-oxyquinoline-
3(4H)-yl)alkyl-(alkaryl-, aryl-) derivative of carboxylic acid 
(PC-66 compound) at both somatic and neuropathic pain 
models. The antinociceptive efficacy of this compound was 
found similar to ketorolac and diclofenac ones, and even 
surpassed them in the activity. It is worthy to note that ef-
fect of the compound was the most evident in Phase I of 
the formalin test, while its influence on the second (inflam-
matory) phase was negligible.  Having compared the actual 
findings with those from the previous studies, according to 
which the compound did not present any damaging effect on 
the stomach both in subchronic and chronic administration 
[7, 8], one may think of the lack of mechanisms of any sig-
nificant  effect on prostaglandin system and high probability 
of involvement of other antinociceptive mechanisms, which 
requires further research of the issue. Conducting in-depth 
studies of mechanisms of analgesic action of 4-oxo (amino-) 
quinazoline derivative (PC-66 compound) and its other ef-
fects may help provide possible indications for its use as a 
medicine with distinctive analgesic effect.
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Table 2
Analgesic activity of РС-66 compared to ketorolac under conditions of intraperitoneal  
administration in rat neuropathic pain model (M ± m, n = 7)
Groups
PT, g/mm2
Intact limb Subject limb
Changes in  pain per-
ception threshold*
In 2 hours after com-
pound administration
Changes in  pain percep-
tion threshold**
Control 406.4±19.9 390.7±22.4 -3.86% 392.1±20.5 +0.35%
PC-66 1 mg/kg 380.7±20.4 298.6±19.7# -21.5% 437.9±29.4& +46.7%
Ketorolac 2.4 mg/kg 407.1±5.76 309.3±17.4# -24.0% 470.0±24.1& +51.9%
Notes: 1. Control – sham-operated animals that received equivolumic quantities of solvents; 2. * – compared to intact limb; 3. ** – compared to 
subject limb before compound administration; 4. # – statistically significant differences (p<0.05) compared to intact limb; 5. &- statistically significant 
differences (p<0.05) compared to subject limb before administration of compounds.
